Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation

Langston, Amelia; Redei, Istvan; Caliendo, Angela M.; Somani, Jyoti; Hutcherson, Donald; Lonial, Sagar; Bucur, Silvana Z.; Cherry, Judy; Allen, Andrew J.; Waller, Edmund K.

doi:10.1182/blood.v99.3.1085

Cited by 80 publications

(66 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They describe three patients who excreted PFA-resistant strains when they received PFA for the first time and two patients, having previously received treatment with PFA, who developed PFA-resistant strains after only 5 and 7 days of treatment. Langston et al (23) described three bone marrow transplantation patients who excreted ACV-resistant HSV strains and who rapidly developed PFA-resistant strains while under treatment with PFA (after 3, 6, and 10 weeks). Alternation of antiviral treatments remains, however, the best strategy for overcoming the emergence of resistant strains, because when antiviral treatment stops, the strains again become sensitive to the antiviral drugs.…”

Section: Discussionmentioning

confidence: 99%

Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up

et al. 2004

View full text Add to dashboard Cite

Herpes simplex virus (HSV) infections are very common in the general population and among immunocompromised patients. Acyclovir (ACV) is an effective treatment which is widely used. We deemed it essential to conduct a wide and coordinated survey of the emergence of ACV-resistant HSV strains . We have formed a network of 15 virology laboratories which have isolated and identified, between May 1999 and April 2002, HSV type 1 (HSV-1) and HSV-2 strains among hospitalized subjects. The sensitivity of each isolate to ACV was evaluated by a colorimetric test (C. Danve, F. Morfin, D. Thouvenot, and M. Aymard, J. Virol. Methods 105:207-217, 2002). During this study, 3,900 isolated strains among 3,357 patients were collected; 55% of the patients were immunocompetent. Only six immunocompetent patients excreted ACV-resistant HSV strains (0.32%), including one female patient not treated with ACV who was infected primary by an ACV-resistant strain. Among the 54 immunocompromised patients from whom ACV-resistant HSV strains were isolated (3.5%), the bone marrow transplantation patients showed the highest prevalence of resistance (10.9%), whereas among patients infected by human immunodeficiency virus, the prevalence was 4.2%. In 38% of the cases, the patients who excreted the ACV-resistant strains were treated with foscarnet (PFA), and 61% of them developed resistance to PFA. The collection of a large number of isolates enabled an evaluation of the prevalence of resistance of HSV strains to antiviral drugs to be made. This prevalence has remained stable over the last 10 years, as much among immunocompetent patients as among immunocompromised patients.Herpes simplex virus (HSV) infections are very common; they are localized on the face and torso in the case of HSV type 1 (HSV-1) and in the genital region in the case of HSV-2. HSV-1 infections in the genital region are on the increase (40). Ocular herpes is less frequent, and neonatal herpes and herpetic meningoencephalitis are very rare but have a severe functional and vital prognosis (37).Since acyclovir (ACV) {9-[(2-hydroxyethoxy)methyl)guanine]} was introduced to the market in 1983, it has been used primarily in the prevention and treatment of HSV infections. ACV-resistant HSV strains have been observed in vivo since the first large therapeutic trials (5, 10, 36). These resistant strains are detected in vitro by phenotypic tests which determine the antiviral concentration inhibiting viral replication by 50%. Several methods have been used to evaluate the sensitivity of the HSV strains to ACV, including techniques to detect the intensity of the cytopathic effect, such as the plaque reduction (17, 31) and colorimetric (11,22,26) techniques, but also the detection of DNA replication by hybridization (39) or antigen production by flow cytometry (30).Previous surveys among immunocompetent patients have shown a prevalence of resistance to ACV varying between 0 and 0.6%, whereas among immunocompromised patients, the prevalence varied between 3 and 6% (9,16,29). The use of ACV is co...

show abstract

Section: Discussionmentioning

confidence: 99%

Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Immunocompetent individuals rarely develop drug resistance, while drug resistance rates up to 36% have been reported for immunosuppressive cases in the literature. In a clinical study on patients with genital herpes, the acyclovir resistance rate has been found to be 0.18% for HIV-negative cases and 5.3% for HIV-positive cases [63][64][65].…”

Section: Cases Of Resistancementioning

confidence: 99%

Genital Herpes

Emre¹,

Akkus²

2017

Fundamentals of Sexually Transmitted Infections

View full text Add to dashboard Cite

Genital herpes simplex virus (HSV) infections are among the most commonly seen sexually transmited infections in the world. Genital herpes is a serious health problem because the infection continues through life with remissions and relapses, it causes recurring painful ulcers, and there is no known cure for it. The real prevalence of the genital herpes infection is unknown due to asymptomatic cases. The majority of infected individuals are not aware of the infection due to short duration of symptoms and signs or its asymptomatic nature. The clinical presentation of genital herpes shows certain differences in terms of the primary atack following the irst encounter with the virus and recurrent atacks. There is a strong relationship between HSV-2 positivity and human immunodeiciency virus (HIV). A serious complication of genital herpes in the mother during pregnancy, neonatal herpes, has a mortality risk of 60% if not treated. Antiviral therapy is safe and efective, for both episodic treatment and chronic suppression of HSV. Epidemiology, clinical presentation, laboratory, and treatment options of genital herpes are summarized in this chapter.

show abstract

“…En casos de resistencia a aciclovir debe utilizarse foscarnet a dosis de 40 mg/kg/8h, por vía parenteral y, en casos de doble resistencia, la única opción terapéutica es el cidofovir (eficaz in vitro pero con respuesta clínica variable). Además, la reconstitución inmune parece ser necesaria para la erradicación de la infección 113 .…”

Section: Virus Herpes Simpleunclassified

Infecciones más comunes en el paciente trasplantado

Yuste

Pozo

Quetglas

et al. 2006

Anales Sis San Navarra

View full text Add to dashboard Cite

Organ transplantation has become one of the most important areas of medical research and, at present, is still the only therapeutical tool for several diseases. However, there are a number of factors related to transplantation, like immunosuppression and prolonged neutropenia that affect the incidence of infection. These infections are somehow peculiar to trasplant recipients. In fact, there are infectious diseases that only occur in immunodepression situations and, moreover, clinical expression of these infectious diseases can be quite different from that in immunocompetent patients. Besides these aspects, some infections, due to the high prevalence described, must be considered for prevention strategies because they continue to be a principal cause of morbidity and mortality, either due to direct effects or to their implication in the pathogenesis of rejection. These strategies commence before trasplantation by active immunization through vaccine administration to the patient and to people in the milieu and continue after trasplantation with prophylaxis or pre-emptive therapy. The importance of infectious diseases in the evolution and prognosis of trasplant recipients gives a special meaning to the understanding of associated infections, their clinical expression and ways of prevention and treatment.

show abstract

Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation

Cited by 80 publications

References 17 publications

Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up

Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up

Genital Herpes

Infecciones más comunes en el paciente trasplantado

Contact Info

Product

Resources

About